Portola Pharmaceuticals

History

Products

• Andexanet alfa, a coagulation factor Xa, inactivated-zhzo, the first and only antidote for patients treated with the new oral anticoagulants rivaroxaban and apixaban when a reversal of anticoagulation is required due to life-threatening or uncontrolled bleeding. Andexanet is not indicated for the treatment of bleeding related to any FXa inhibitors other than apixaban and rivaroxaban. Approved by FDA in May, 2018. In February 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for Andexanet alfa. In April 2019 the European Commission granted the authorisation Andexanet for the 28 countries of the EU.
• Betrixaban, an oral direct FXa inhibitor for prevention of thrombosis; approved by FDA in June, 2017.
• Cerdulatinib, an investigational - not approved - oral multikinase SYK/JAK inhibitor for hematological malignancies and topical use; granted Orphan drug status for PTCL by FDA in September, 2018.